Connect with us

Stock Market Breaking News

ParcelPal (PTNYF)(PKG) Signs Agreement for Marijuana Distribution With Choom Holdings Inc.

Joe Samuel

Published

on

VANCOUVER , Sept. 27, 2018 /CNW/ – ParcelPal Technology Inc. (“ParcelPal” or the “Company”), (PKG.CN) (PT0.F) (PTNYF) – is pleased to announce they have signed an agreement for Cannabis distribution with Vancouver, BC based Choom Holdings, Inc, (“Choom”) (CSE:C HOO) (CHOOF) Canada’s leading cannabis retailer.

Further to the marijuana strategy announced on September 13, 2018 , ParcelPal has made their first footprint into the marijuana industry through signing an agreement with Choom Holdings Inc. (CSE:CHOO). The Company received the agreement from Choom for the establishment of distribution from various retail outlets in Canada . The initiative will consist of:

Distribution: ParcelPal and Choom will jointly develop the optimal roadmap for distribution within various provinces for adult use cannabis.

Accessibility: Using Choom’s and ParcelPal’s platform to enhance user experience and accessibility to products offered.

Compliance: ParcelPal and Choom will ensure that all products will be delivered will be within the parameters set forth by all regulating bodies in Canada.

Safety: ParcelPal and Choom are dedicated to public safety by enabling safe access to product for consumers through an instant delivery channel; eliminating impaired driving.

President and CEO Kelly Abbott States , “We are extremely pleased and excited to have this agreement from Choom and fully intend to utilize other partnership opportunities to forward our national cannabis distribution and delivery strategy. Our contemplation is to be the Uber of cannabis for Canada and grow our revenues exponentially through this vertical.” Abbott continued, “Current options, such as Canada Post or other antiquated courier services are expensive, may take up to 7 days and are fraught with service interruptions such as strikes. With ParcelPal, consumers can get their requested product easily and safely within an hour. Our innovative technology enables seamless integration with any retail outlet for cannabis.”

President and CEO Chris Bogart from Choom states, “We recognize the importance of utilizing the existing technology of ParcelPal’s mobile app in concert with their outstanding track record of home delivery execution. We believe this will provide an exceptional customer experience and we are excited to offer this to our valued customers upon the upcoming rollout of our retail strategy.”

About Choom Holdings Inc.

The Choom brand is inspired by Hawaii’s “Choom Gang” – a group of buddies in Honolulu during the 1970’s who loved to smoke weed-or as the locals called it, choom. Evoking the spirit of the original Choom Gang , our brand is synonymous with cultivating good times with good friends. Choom is focused on delivering an elevated customer experience through our curated retail environments, high-grade handcrafted cannabis supply, and a diversity of brands for the Canadian recreational consumer. Find more about Choom from their website: http://www.choom.ca

About ParcelPal Technology Inc.

ParcelPal is a technology driven logistics company that connects consumers to the goods they love. Customers can shop at partner businesses and through the ParcelPal technology receive their purchased goods within an hour. The Company offers on-demand delivery of merchandise from leading retailers, restaurants, medical marijuana dispensaries and liquor stores in Vancouver and soon in major cities Canada -wide.

ParcelPal Website: http://www.parcelpal.com

The Canadian Securities Exchange (“CSE”) or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release that has been prepared by management.

CSE – Symbol: PKG

FSE – Symbol: PT0

OTC – Symbol: PTNYF

Forward Looking Information

This news release contains forward looking statements relating to the Proposed Transaction, and the future potential of ParcelPal. Forward looking statements are often identified by terms such as “will”, “may”, “should”, “intends”, “anticipates”, “expects”, “plans” and similar expressions. All statements other than statements of historical fact, included in this release are forward looking statements that involve risks and uncertainties. These risks and uncertainties include, without limitation, the risk that the Proposed Transaction will not be completed due to, among other things, failure to execute definitive documentation, failure to complete satisfactory due diligence, failure to receive the approval of the CSE and the risk that ParcelPal will not be successful due to, among other things, general risks relating to the mobile application industry, failure of ParcelPal to gain market acceptance and potential challenges to the intellectual property utilized in ParcelPal. There can be no assurance that any forward looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

The Company cannot guarantee that any forward looking statement will materialize and the reader is cautioned not to place undue reliance on any forward looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward looking statements contained in this news release are expressly qualified by this cautionary statement. The forward looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward looking statements as expressly required by Canadian securities laws.

SOURCE ParcelPal Technology Inc.

Continue Reading
Click to comment

Featured

ParcelPal (PTNYF) (PKG) Announces Delivery Agreement with Aphria Inc. (APHA)

Joe Samuel

Published

on

defense industry merger

VANCOUVER, British Columbia , Aug. 22, 2019 /CNW/ — ParcelPal Technology Inc. (“ParcelPal” or the “Company”), (PKG.CN) (PT0.F) (PTNYF) is pleased to announce that it secured a distribution agreement with one of the largest Canadian Federally Licensed producers in Canada , Aphria Inc. (“Aphria”) (APHA.TO) (APHA) for delivery of medical cannabis to patients.

This initiative between ParcelPal and Aphria will commence with Calgary as the catalyst city. Patients can purchase product from Aphria’s online store and utilize the ParcelPal technology platform to receive their product safely and legally. All customers will be able to track their purchase in real time and have their product delivered directly to any location they specify within Calgary .

In collaboration with ParcelPal, and MADD Canada are confident that this program will not only enable consumers unfettered access to their medicinal cannabis in a safe and timely manner but will furthermore assist in eliminating impaired drivers from our roadways by removing their need to drive to or from cannabis stores for product.

ParcelPal expects that additional cities will be rapidly added to its distribution network across Canada . As time and regulations allow, ParcelPal’s cannabis network will continue to grow, with the goal of capturing a major piece of Canada’s $4.0B legal cannabis market.

President and CEO, Kelly Abbott states, “The legal cannabis space continues to serve as a sector filled with significant growth potential for ParcelPal. Management believes that we are launching our legal cannabis delivery platform at the ideal time as legislation across the country continues to expand the addressable cannabis marketplace and we are thrilled to be working with Aphria on this exciting new venture that will help to kick off the next evolution of our company. We expect to leverage numerous business opportunities in the upcoming year. We look forward to establishing ourselves as a market leader in the cannabis delivery space and capturing meaningful market share in 2019 and beyond.”

About ParcelPal Technology Inc.

ParcelPal is a technology-driven logistics company that connects consumers to the goods they love. Customers can shop at partner businesses and through the ParcelPal technology receive their purchased goods within an hour. The Company offers on-demand delivery of merchandise from leading retailers, restaurants, marijuana dispensaries and liquor stores in Vancouver and soon in major cities Canada -wide.

ParcelPal Website: www.parcelpal.com

The Canadian Securities Exchange (“CSE”) or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release that has been prepared by management.

CSE – Symbol: PKG
FSE – Symbol: PT0
OTC – Symbol: PTNYF

Forward Looking Information.

We seek safe harbour.

This news release contains forward looking statements relating to the Proposed Transaction, and the future potential of ParcelPal. Forward looking statements are often identified by terms such as “will”, “may”, “should”, “intends”, “anticipates”, “expects”, “plans” and similar expressions. All statements other than statements of historical fact, included in this release are forward looking statements that involve risks and uncertainties. These risks and uncertainties include, without limitation, the risk that the Proposed Transaction will not be completed due to, among other things, failure to execute definitive documentation, failure to complete satisfactory due diligence, failure to receive the approval of the CSE and the risk that ParcelPal will not be successful due to, among other things, general risks relating to the mobile application industry, failure of ParcelPal to gain market acceptance and potential challenges to the intellectual property utilized in ParcelPal. There can be no assurance that any forward looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

The Company cannot guarantee that any forward looking statement will materialize and the reader is cautioned not to place undue reliance on any forward looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward looking statements contained in this news release are expressly qualified by this cautionary statement. The forward looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward looking statements as expressly required by Canadian securities laws.

Contact:
Peter Hinam
Investor Relations
peter@parcelpal.com
+1-604-401-8700

View original content on PRNewswire.com: http://www.prnewswire.com/news-releases/parcelpal-announces-delivery-agreement-with-aphria-inc-300905818.html

MIDAM VENTURES LLC has been compensated $75,000 per month by a ParcelPal Technology, Inc. for a period beginning September 1, 2018 and ending February 1, 2019 to publicly disseminate information about (PTNYF/PKG) to publicly disseminate information about (PTNYF/PKG). Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to April 1, 2019. Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to May 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to June 1, 2019. Midam Ventures has been compensated $200,000 by Parcel Pal and has extended coverage to July 1, 2019. We may buy or sell additional shares of (PTNYF/PKG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares. Read Full Disclaimer Here

Continue Reading

Biotechnology

PharmaCyte Biotech to Hold Special Shareholder Meeting

A. Lawrence

Published

on

biotechnology stock price

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–

PharmaCyte Biotech, Inc. (PMCB), a clinical-stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will hold a Special Shareholder Meeting on September 11, 2019. The shareholder meeting, not to be confused with a shareholder conference call, will be held at the Courtyard by Marriott in Irvine, California, and will begin at 11:00 a.m. Pacific Daylight Time.

During the meeting there will be an update on PharmaCyte’s current research-related projects followed by a question and answer session regarding the update. The meeting will then turn to management matters, such as: (i) amending PharmaCyte’s Articles of Incorporation to provide the Board of Directors (“Board”) the power to designate the rights and preferences of PharmaCyte’s preferred stock; (ii) election of six directors as nominated by the Board’s Nominating Committee and approved by the Board, each to serve a one-year term; (iii) ratification of the appointment of Armanino LLP as PharmaCyte’s independent registered public accounting firm for the fiscal year ending April 30, 2020 and (iv) to consider and act upon any other business as may properly come before the Special Shareholder Meeting.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “This shareholder meeting will be the first during my tenure as CEO. Since the new management team took over in 2014, we have faced untold challenges and hurdles virtually every day. We have persevered. We believe we’re on the brink of a new dawn for the company as we work collaboratively with so many stellar professional colleagues to showcase the unique Cell-in-a-Box® technology in which so many have worked so diligently over the past several years. We feel that it is important to realize our full potential while, at the same time, bringing value to and protecting our shareholders who have stood by us for so long.

“We look forward to meeting many of our long-standing and new shareholders who can attend and in implementing the steps that will enable us to succeed on numerous fronts.”

About PharmaCyte Biotech:

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190821005275/en/

Contact:
Dr. Gerald W. Crabtree
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Featured

Stock Price Wednesday Morning Update – August 21, 2019

Joe Samuel

Published

on

biotech stocks to watch

PharmaCyte Biotech to Hold Special Shareholder Meeting

PharmaCyte Biotech, Inc. (PMCB), a clinical-stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will hold a Special Shareholder Meeting on September 11, 2019.

See More On This – CLICK HERE


Must Read Biotech Stock Report

With a wave of groundbreaking products in the pipeline, biotechnology could be poised to keep churning higher for the foreseeable future. But how can you get in on the ground floor of the next big wave in biotech?

Continue Reading


2 Food Delivery Stocks To Watch Before The End Of Summer

The food delivery industry in the United States has grown into a behemoth and although the margins are extremely thin, investors are willing to bet billions on some of the biggest food delivery companies. At this point in time, companies are fighting among themselves to gain supremacy in this space and competition is heating up as they look to grab market share from each other.

Read More Here


2 Chinese Stocks Making Bullish Moves

The trade war with the United States and an economic slowdown for the first time in three decades has cratered the markets in China. China-based stocks have generally underperformed over the course of the past year. But even during such a slowdown, some stock prices have been showing bullish tendencies. Here is a look at two such China-based companies that have seen stock prices climb.

See For Yourself

biotech stock to buy 2019

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com